Infection Prophylaxis for Neutropenia (WBC 1.8 × 10³/µL)
The decision to initiate prophylaxis depends critically on the absolute neutrophil count (ANC), expected duration of neutropenia, and underlying disease risk—not just the total WBC count alone. You must first calculate the ANC to determine if true neutropenia exists (ANC ≤500/µL or ≤1000/µL with predicted decline to ≤500/µL) 1.
Risk Stratification Algorithm
Step 1: Calculate ANC and Assess Duration
- If ANC >1000/µL without predicted decline: No prophylaxis needed
- If ANC ≤500/µL OR ANC ≤1000/µL with predicted decline to ≤500/µL: Proceed to Step 2
Step 2: Determine Expected Duration of Neutropenia
For neutropenia expected <7 days (most solid tumor standard chemotherapy):
- No antibacterial prophylaxis recommended 1
- No antifungal prophylaxis
- No antiviral prophylaxis unless prior HSV episode
For neutropenia expected 7-10 days (intermediate risk: autologous HCT, lymphoma, multiple myeloma, CLL, purine analogs, CAR T-cell therapy):
- Consider fluoroquinolone prophylaxis (levofloxacin preferred) 1
- Consider antifungal prophylaxis during neutropenia and anticipated mucositis
- Consider PJP prophylaxis
- Consider antiviral prophylaxis
For neutropenia expected >10 days (high risk: allogeneic HCT, acute leukemia induction/consolidation, alemtuzumab, moderate-severe GVHD):
- Fluoroquinolone prophylaxis recommended (levofloxacin preferred) 1, 2
- Antifungal prophylaxis recommended (oral triazole or parenteral echinocandin); use mold-active triazole when invasive aspergillosis risk >6% 2
- PJP prophylaxis recommended
- Antiviral prophylaxis recommended
Specific Prophylaxis Regimens
Antibacterial
- First-line: Levofloxacin during period of neutropenia 1, 2
- If fluoroquinolone intolerant: TMP-SMX or oral third-generation cephalosporin (category 2B) 1
Special Populations
- Allogeneic HCT with chronic GVHD: Add penicillin prophylaxis starting 3 months post-HCT, continue until at least 1 year or until immunosuppression discontinued 1
- High-risk patients on ≥20mg prednisone daily for ≥1 month or purine analogs: TMP-SMX for PJP prophylaxis 2
- HSV-seropositive patients undergoing HSCT or leukemia induction: Acyclovir prophylaxis 2
Critical Caveats
Fluoroquinolone prophylaxis carries significant risks that must be weighed against benefits 1:
- Emergence of multidrug-resistant organisms
- Increased risk of Clostridioides difficile infection
- Increased risk of methicillin-resistant S. aureus infections
- Microbiome disruption
- May preclude use as empirical therapy for subsequent febrile neutropenia
The 2025 Australian consensus guidelines 3 present a contrasting view, concluding that in most circumstances, the harms of antibiotic resistance, adverse effects, and microbiome disruption outweigh benefits when there is no demonstrated mortality reduction. However, the 2024 NCCN guidelines 1 and 2018 ASCO/IDSA guidelines 2 remain the current standard in North America, showing mortality benefit particularly with fluoroquinolones in high-risk populations (NNT 55 for acute leukemia/BMT patients) 4.
Bottom Line
Without knowing the ANC, underlying malignancy, chemotherapy regimen, and expected duration of neutropenia, you cannot make an evidence-based prophylaxis decision. A WBC of 1.8 × 10³/µL alone is insufficient—obtain differential count immediately and apply the risk stratification algorithm above.